VahatiCor secures $23 million in Series B funding led by S3 Ventures to enhance A-FLUX® development for coronary microvascular dysfunction.
PRIVATENov 18, 2025
Amount Raised
$23 Million
Round Type
Series B
Santa ClaraBiotechnologyHealth CareMedicalTherapeutics
Investors
Intuitive VenturesS3 Ventures
Description
VahatiCor has closed an oversubscribed $23 million Series B financing round. This funding led by S3 Ventures will aid in advancing the SERRA-I feasibility study and subsequent regulatory preparations. The new capital will support ongoing engineering development and pivotal trials. VahatiCor aims to enhance treatment options for millions suffering from coronary microvascular dysfunction.
Company Information
Company
VahatiCor
Location
Santa Clara, California, United States
About
VahatiCor is a medtech company dedicated to transforming cardiac care for Coronary Microvascular Dysfunction (CMD). They are focused on developing innovative therapies, particularly the A-FLUX Reducer System®, which aims to enhance myocardial perfusion and relieve symptoms of angina for millions affected by CMD. The company is currently advancing clinical studies and preparing for pivotal trials to bring their breakthrough therapies to market. Their mission is to improve the quality of life for patients suffering from this often overlooked medical condition.
Fundz sees it the moment VahatiCor raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Santa ClaraBiotechnologyHealth CareMedicalTherapeutics